<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68983">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02207777</url>
  </required_header>
  <id_info>
    <org_study_id>201403065</org_study_id>
    <secondary_id>1R01DK101578</secondary_id>
    <nct_id>NCT02207777</nct_id>
  </id_info>
  <brief_title>Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes</brief_title>
  <acronym>RBD-T2D</acronym>
  <official_title>Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For this purpose, we will compare the effects of 16-18% weight loss induced by Roux-en Y
      Gastric bypass (RYGB) surgery, biliopancreatic diversion with duodenal switch (BPD), or
      sleeve gastrectomy (SG) surgeries with the same weight loss induced by laparoscopic
      adjustable gastric banding (LAGB) or a low-calorie diet (LCD) on liver and skeletal muscle
      insulin sensitivity, beta-cell function, and 24-hour metabolic homeostasis in obese subjects
      with T2D.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic and skeletal muscle insulin sensitivity</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-cell function</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Roux-en-Y gastric bypass (RYGB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain a 16-18% weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-calorie diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will participate in a low-calorie diet intervention to obtain a 16-18% weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPD surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group are scheduled to undergo BPD surgery to obtain a 16-18% weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve Gastrectomy (SG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group are scheduled to undergo SG surgery to obtain a 16-18% weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAGB Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will either be already scheduled to undergo LAGB surgery or to obtain a 16-18% weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass surgery</intervention_name>
    <description>A surgical procedure to help subjects lose 16-18% of their body weight.</description>
    <arm_group_label>Roux-en-Y gastric bypass (RYGB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low-calorie diet</intervention_name>
    <description>Subjects will meet with a dietitian over 4-6 months to lose 16-18% of their body weight.</description>
    <arm_group_label>Low-calorie diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BPD</intervention_name>
    <description>Bilopancreatic Diversion with duodenal switch (BPD) is a surgical procedure to help subjects lose 16-18% of their body weight.</description>
    <arm_group_label>BPD surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SG</intervention_name>
    <description>Sleeve Gastrectomy (SG) is a surgical procedure to help subjects lose 16-18% of their body weight.</description>
    <arm_group_label>Sleeve Gastrectomy (SG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LAGB</intervention_name>
    <description>Laparoscopic Adjustable Gastric Banding is a surgical procedure to help subjects lose 16-18% of their body weight.</description>
    <arm_group_label>LAGB Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        RYGB/BPD/SG/LAGB

          -  Scheduled for one of these bariatric surgeries

          -  Body Mass Index (BMI) 35-55 kg/m²

          -  Type 2 Diabetes and Non Diabetics

          -  Signed informed consent Low-Calorie Diet

          -  BMI 35-55 kg/m²

          -  Type 2 Diabetes and Non Diabetics

          -  Signed informed consent

        Exclusion Criteria:

        RYGB/BPD/SG &amp; Low-Calorie Diet

          -  Regular use of tobacco products

          -  Previous intestinal resection

          -  Pregnant or breastfeeding

          -  Evidence of significant organ system dysfunction or disease other than T2D

          -  Use of any medication that might, in the opinion of the investigator, affect
             metabolic function

          -  Exercise &gt;= to 90 minutes per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Sonnenscein, BA</last_name>
    <phone>314-747-2627</phone>
    <email>j.sonnenschein@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melisa Moore, BSN</last_name>
    <phone>314-362-8604</phone>
    <email>mmoore@dom.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Sonnenschein, BA</last_name>
      <phone>314-747-2627</phone>
      <email>j.sonnenschein@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melisa Moore, BSN</last_name>
      <phone>314-362-8604</phone>
      <email>mmoore@dom.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Samuel Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihoko Yoshino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 13, 2016</lastchanged_date>
  <firstreceived_date>July 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Roux-en-Y gastric bypass (RYGB)</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Sleeve Gastrectomy (SG)</keyword>
  <keyword>Biliopancreatic Diversion with Duodenal switch (BPD)</keyword>
  <keyword>Laparoscopic Adjustable Gastric Banding (LAGB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
